Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation (Cell Death & Disease, (2016), 7, 10, (e2419), 10.1038/cddis.2016.268);Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation

Cell Death and Disease

Volumn 7, Issue 10, 2016, Pages

  Javaheri, Tahereh ^a,b   Kazemi, Zahra ^c   Pencik, Jan ^a,c,d   Pham, Ha T T ^a,b   Kauer, Maximilian ^e   Noorizadeh, Rahil ^a,b   Sax, Barbara ^a   Nivarthi, Harini ^a,f   Schlederer, Michaela ^a,c,d   Maurer, Barbara ^a,b   Hofbauer, Maximillian ^a   Aryee, Dave N T ^c,e   Wiedner, Marc ^a,f   Tomazou, Eleni M ^e   Logan, Malcolm ^g   Hartmann, Christine ^h   Tuckermann, Jan P ⁱ   Kenner, Lukas ^a,b,c,d   Mikula, Mario ^c   Dolznig, Helmut ^c   Üren, Aykut ^j   Richter, Günther H ^k   Grebien, Florian ^a   Kovar, Heinrich ^c,e   Moriggl, Richard ^a,b,c   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Clinical Institute of Pathology   (Austria)

^e ST ANNA CHILDREN S HOSPITAL   (Austria)

^f ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ UNIVERSITY OF ULM   (Germany)

^j GEORGETOWN UNIVERSITY   (United States)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BETA CATENIN; CASPASE 3; COLLAGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; FUSION PROTEIN; OBATOCLAX; PAIRED RELATED HOMEOBOX 1; PALBOCICLIB; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; RNA BINDING PROTEIN EWS; SMAD1 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; EWS-FLI FUSION PROTEIN; MCL1 PROTEIN, MOUSE; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CHILDHOOD CANCER; CHONDROCYTE; CONTROLLED STUDY; EMBRYO; EWING SARCOMA; EWING SARCOMA CELL LINE; GENE KNOCKDOWN; HUMAN; HUMAN CELL; IC50; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; STEM CELL SELF-RENEWAL; ANIMAL; BONE; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL TRANSFORMATION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN EMBRYONIC STEM CELL; LIMB; MESENCHYMAL STROMA CELL; METABOLISM; NEWBORN; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BONE AND BONES; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; EXTREMITIES; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMAN EMBRYONIC STEM CELLS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; ONCOGENE PROTEINS, FUSION; OSTEOGENESIS; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA-BINDING PROTEIN EWS; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC;

EID: 85008719014     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-019-1853-1     Document Type: Erratum

References (48)

1. Minas TZ, Han J, Javaheri T, Hong SH, Schlederer M, Saygideger-Kont Y et al. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget 2015; 6: 37678–37694.
2. Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV et al. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget 2014; 5: 338–350.
3. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009; 15: 750–756.
4. Pencik J, Pham HT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z et al. JAK-STAT signaling in cancer: from cytokines to non-coding genome. Cytokine 2016; S1043-4666: 30145–4.
5. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008; 68: 2176–2185.
6. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11: 421–429.
7. Tanaka M, Yamazaki Y, Kanno Y, Igarashi K, Aisaki K, Kanno J et al. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. J Clin Invest 2014; 124: 3061–3074.
8. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL Jr. Expression of the EWS/ FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 2005; 65: 8698–8705.
9. Leacock SW, Basse AN, Chandler GL, Kirk AM, Rakheja D, Amatruda JF. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Dis Model Mech 2012; 5: 95–106.
10. Torchia EC, Boyd K, Rehg JE, Qu C, Baker SJ. EWS/FLI-1 induces rapid onset of myeloid/ erythroid leukemia in mice. Mol Cell Biol 2007; 27: 7918–7934.
11. Sohn EJ, Li H, Reidy K, Beers LF, Christensen BL, Lee SB. EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo. Cancer Res 2010; 70: 1154–1163.
12. Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008; 68: 8968–8975.
13. Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ. Expression of Cre Re-combinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 2002; 33: 77–80.
14. Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget 2016 (doi:10.18632/oncotarget.9388; e-pub ahead of print).
15. Hsieh HY, Hsiao CC, Chen WS, Lin JW, Chen WJ, Wan YL et al. Congenital Ewing's sarcoma of the humerus. Br J Radiol 1998; 71: 1313–1316.
16. Rosa M, Mohammadi A, Campos M, Garcia-Garcia I, Correa-Rivas MS. Congenital EWS/ pPNET presenting as a neck mass. Pediatr Blood Cancer 2009; 53: 678–679.
17. Burgers TA, Williams BO. Regulation of Wnt/beta-catenin signaling within and from osteocytes. Bone 2013; 54: 244–249.
18. Dao DY, Jonason JH, Zhang Y, Hsu W, Chen D, Hilton MJ et al. Cartilage-specific beta-catenin signaling regulates chondrocyte maturation, generation of ossification centers, and perichondrial bone formation during skeletal development. J Bone Miner Res 2012; 27: 1680–1694.
19. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 2006; 99: 1233–1239.
20. Zhang DY, Pan Y, Zhang C, Yan BX, Yu SS, Wu DL et al. Wnt/beta-catenin signaling induces the aging of mesenchymal stem cells through promoting the ROS production. Mol Cell Biochem 2013; 374: 13–20.
21. Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003; 278: 34387–34394.
22. Travis MA, Sheppard D. TGF-beta activation and function in immunity. Annu Rev Immunol 2014; 32: 51–82.
23. Schlederer M, Mueller KM, Haybaeck J, Heider S, Huttary N, Rosner M et al. Reliable quantification of protein expression and cellular localization in histological sections. PloS One 2014; 9: e100822.
24. Long F, Ornitz DM. Development of the endochondral skeleton. Cold Spring Harb Perspect Biol 2013; 5: a008334.
25. Munoz-Espin D, Canamero M, Maraver A, Gomez-Lopez G, Contreras J, Murillo-Cuesta S et al. Programmed cell senescence during mammalian embryonic development. Cell 2013; 155: 1104–1118.
26. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229–249.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
28. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P et al. A molecular function map of Ewing's sarcoma. PloS One 2009; 4: e5415.
29. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226–9235.
30. Huskey NE, Guo T, Evason KJ, Momcilovic O, Pardo D, Creasman KJ et al. CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation. Stem Cell Rep 2015; 4: 374–389.
31. Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim MY et al. Myeloid cell leukemia-1 is associated with tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer. Am J Cancer Res 2015; 5: 101–113.
32. Arnaldez FI, Helman LJ. New strategies in ewing sarcoma: lost in translation? Clin Cancer Res 2014; 20: 3050–3056.
33. Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res 2004; 64: 6026–6034.
34. Kowalewski AA, Randall RL, Lessnick SL. Cell cycle deregulation in Ewing's sarcoma pathogenesis. Sarcoma 2011; 2011: 598704.
35. Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget 2015; 6: 30178–30193.
36. Obexer P, Hagenbuchner J, Rupp M, Salvador C, Holzner M, Deutsch M et al. p16INK4A sensitizes human leukemia cells to FAS-and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2. J Biol Chem 2009; 284: 30933–30940.
37. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014; 4: 1342–1353.
38. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009; 284: 9074–9082.
39. Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23: 222–227.
40. Li X, McGee-Lawrence ME, Decker M, Westendorf JJ. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J Cell Biochem 2010; 111: 933–943.
41. Sederquist B, Fernandez-Vojvodich P, Zaman F, Savendahl L. Recent research on the growth plate: Impact of inflammatory cytokines on longitudinal bone growth. J Mol Endocrinol 2014; 53: T35–T44.
42. Hauer K, Calzada-Wack J, Steiger K, Grunewald TG, Baumhoer D, Plehm S et al. DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. Cancer Res 2013; 73: 967–977.
43. Scannell CA, Pedersen EA, Mosher JT, Krook MA, Nicholls LA, Wilky BA et al. LGR5 is expressed by Ewing sarcoma and potentiates Wnt/beta-catenin signaling. Front Oncol 2013; 3: 81.
44. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T et al. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 2008; 28: 2125–2137.
45. Matsumoto Y, Tanaka K, Nakatani F, Matsunobu T, Matsuda S, Iwamoto Y. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1) regulatory genes. Br J Cancer 2001; 84: 768–775.
46. Sollazzo MR, Benassi MS, Magagnoli G, Gamberi G, Molendini L, Ragazzini P et al. Increased c-myc oncogene expression in Ewing's sarcoma: correlation with Ki67 proliferation index. Tumori 1999; 85: 167–173.
47. Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol 2003; 56: 96–102.
48. Lyashenko N, Weissenbock M, Sharir A, Erben RG, Minami Y, Hartmann C. Mice lacking the orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded. Dev Dyn 2010; 239: 2266–2277.